Phase II study of pemetrexed maintenance with or without bevacizumab after a first line treatment chemotherapy with bevacizumab-carboplatin-pemetrexed in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000010002
- Lead Sponsor
- Internal Medicine 2, Hamamatsu University School of Medicine.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
interstitial lung disease history of hemoptysis myocardial infarction,unstable angina, stroke, transient ischemic attack significant vascular disease bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation hypertension or history of hypertensive crisis or encephalopathy; known CNS disease, except brain metastases treated with radiotherapy pregnancy abdominal fistula, or gastrointestinal perforation poorly controlled active ulcer known hypersensitivity to drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival for 9 months
- Secondary Outcome Measures
Name Time Method